ArticleScientific reports2025
Changing epidemiology, prescription and outcomes of acute kidney injury patients treated by peritoneal dialysis during 20 years: a cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal dialysis (PD) for AKI patients using a flexible catheter and cycler was started in 2004 in Botucatu, São Paulo, Brazil. This study aimed to describe the main determinants of patient and technique survival, including PD treatment trends in AKI patients over time. This was a large Brazilian retrospective cohort study in which adult AKI patients with PD were studied from January/2004 to January/2024. For comparison purposes, patients were divided into two groups according to the year of treatment: 2004-2014 and 2015-2024. We included 487 patients. The mean age was 64.02 ± 15.01 years and 327 (67.1%) patients were male. Most patients needed vasoactive drugs and mechanical ventilation (66.1% and 73.1%, respectively). The mean ATN-index specific score (ISS) was 0.61 ± 0.2, and the median APACHE-II score was 27 (20-31). Sepsis was the primary diagnosis (33.7%), followed by cardiovascular etiologies (29.2%). Uremia or azotemia was the main indication for dialysis (46.4%). The delivered urea Kt/V was 0.55 ± 0.18/session and 3.22 ± 0.6/week. Over the years, the prevalence of catabolism increased from 7.6 to 26.5% (p < 0.0001), and PD has been used more in patients with liver cirrhosis (from 5.3 to 14.1%, p < 0.0001) and with nephrotoxic AKI (from 0 to 5.9%, p < 0.0001), and less in septic patients (40.1 vs. 23.2%). The groups were similar in terms of APACHE2. The indication for dialysis due to azotemia/uremia decreased from 64.9% to 16.2% (p < 0.0001) and increased by metabolic and fluid demand to capacity imbalance (from 4 to 68.1%, p < 0.0001). The prescribed dialysis PD dose decreased from 0.56 ± 0.09 to 0.44 ± 0.08 (p < 0.001), and there was no difference in metabolic and volume control. There was an increase in kidney function recovery from 24.8 to 35.7% (p < 0.0001) and a reduction in mortality over 30 days from 59.9% to 49.2% (p 0.02) and in technical failure (TF) from 15.6% to 5.9% (p < 0.0001). The main cause of TF was mechanical complication followed by peritonitis. Cox regression identified the period 2004-2014 as a risk factor for death and technique failure (OR 2.4, 95%CI 1.16-4.93, p = 0.018, and OR 12.58, 95%CI 2.74-57.69, p = 0.001, respectively). In the second period, PD was indicated earlier and prescribed at a lower dose, with no difference in the patient's metabolic and volume control. There was an improvement in patient survival and technique over the years, suggesting better indication and management of this therapy. This is the largest cohort in the world to provide patient characteristics, clinical practice, and its relationship with clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.